Mohammed A. Aljama

540 total citations
33 papers, 252 citations indexed

About

Mohammed A. Aljama is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Mohammed A. Aljama has authored 33 papers receiving a total of 252 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 15 papers in Molecular Biology and 11 papers in Genetics. Recurrent topics in Mohammed A. Aljama's work include Multiple Myeloma Research and Treatments (18 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (8 papers). Mohammed A. Aljama is often cited by papers focused on Multiple Myeloma Research and Treatments (18 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (8 papers). Mohammed A. Aljama collaborates with scholars based in United States, Canada and Saudi Arabia. Mohammed A. Aljama's co-authors include M Hasib Sidiqi, Morie A. Gertz, David Dingli, Hagen F. Kennecke, Rahma Warsame, William J. Hogan, Angela Dispenzieri, Taxiarchis Kourelis, Martha Q. Lacy and Prashant Kapoor and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Mohammed A. Aljama

30 papers receiving 249 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mohammed A. Aljama United States 8 165 102 90 75 64 33 252
Nancy Bello United States 3 276 1.7× 88 0.9× 76 0.8× 61 0.8× 110 1.7× 3 295
Sossana Delimpasi Greece 8 171 1.0× 159 1.6× 84 0.9× 26 0.3× 85 1.3× 13 243
Nobuya Hiraoka Japan 9 78 0.5× 43 0.4× 74 0.8× 32 0.4× 44 0.7× 22 254
Ami Patel United States 9 82 0.5× 54 0.5× 66 0.7× 18 0.2× 23 0.4× 24 261
Anthony C Shelton United States 11 543 3.3× 217 2.1× 131 1.5× 132 1.8× 247 3.9× 38 574
Shuichi Shirane Japan 8 188 1.1× 233 2.3× 32 0.4× 18 0.2× 293 4.6× 35 375
Robert Greiner United States 5 27 0.2× 65 0.6× 34 0.4× 25 0.3× 47 0.7× 22 218
Luděk Pour Czechia 8 79 0.5× 61 0.6× 69 0.8× 17 0.2× 25 0.4× 88 206
Zonghong Shao China 12 76 0.5× 209 2.0× 47 0.5× 30 0.4× 47 0.7× 48 371
Toshikazu Akioka Japan 9 35 0.2× 34 0.3× 79 0.9× 31 0.4× 47 0.7× 34 264

Countries citing papers authored by Mohammed A. Aljama

Since Specialization
Citations

This map shows the geographic impact of Mohammed A. Aljama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammed A. Aljama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammed A. Aljama more than expected).

Fields of papers citing papers by Mohammed A. Aljama

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammed A. Aljama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammed A. Aljama. The network helps show where Mohammed A. Aljama may publish in the future.

Co-authorship network of co-authors of Mohammed A. Aljama

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammed A. Aljama. A scholar is included among the top collaborators of Mohammed A. Aljama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammed A. Aljama. Mohammed A. Aljama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Haider, Imran, Darryl P. Leong, Martha Louzada, et al.. (2024). Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL). Blood. 144(Supplement 1). 703–703. 1 indexed citations
3.
Haider, Imran, Gregory R. Pond, Mohammed A. Aljama, et al.. (2024). A structured oral chemotherapy teaching tool to improve adherence in adults with multiple myeloma: A pilot randomized controlled trial. Journal of Geriatric Oncology. 15(3). 101735–101735.
4.
5.
Berinstein, Neil L., Kees-Peter de Roos, Rebecca F. McClure, et al.. (2023). Indolent lymphoma: Bendamustine, rituximab and acalabrutinib in Waldenstroms Macroglobulinemia (BRAWM). Hematological Oncology. 41(S2). 396–397. 1 indexed citations
6.
Visram, Alissa, Hsien Seow, Gregory R. Pond, et al.. (2023). Treatment Patterns and Healthcare Resource Utilization Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Blood. 142(Supplement 1). 3774–3774. 1 indexed citations
7.
Aghel, Nazanin, Hira Mian, Christopher Hillis, et al.. (2023). Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis. Bone Marrow Transplantation. 58(5). 478–490. 2 indexed citations
8.
Mian, Agrima, Syed Arsalan Ahmed Naqvi, Muhammad Husnain, et al.. (2023). Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis. Leukemia Research. 131. 107324–107324. 7 indexed citations
9.
Seow, Hsien, Gregory R. Pond, Tanya M. Wildes, et al.. (2023). Risk of cancer-specific death among octogenarians with multiple myeloma: A population-based analysis. Journal of Geriatric Oncology. 14(8). 101592–101592. 1 indexed citations
10.
Naqvi, Syed Arsalan Ahmed, et al.. (2022). Post Autologous Stem Cell Transplant Maintenance in Patients with Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis. Blood. 140(Supplement 1). 10111–10113. 2 indexed citations
11.
Sidiqi, M Hasib, et al.. (2019). The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors. Acta Haematologica. 143(2). 118–123. 19 indexed citations
12.
Sidiqi, M Hasib, Abdullah S. Al Saleh, Nelson Leung, et al.. (2019). PF625 VENETOCLAX FOR THE TREATMENT OF TRANSLOCATION (11; 14) AL AMYLOIDOSIS. HemaSphere. 3(S1). 265–266. 1 indexed citations
13.
Sidiqi, M Hasib, Mohammed A. Aljama, Dragan Jevremović, et al.. (2018). Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation. 24(11). 2360–2364. 9 indexed citations
14.
Sidiqi, M Hasib, Mohammed A. Aljama, Eli Muchtar, et al.. (2018). Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. Bone Marrow Transplantation. 54(7). 1077–1081. 5 indexed citations
15.
Sidiqi, M Hasib, Mohammed A. Aljama, Eli Muchtar, et al.. (2018). Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. Biology of Blood and Marrow Transplantation. 24(10). 2157–2159. 7 indexed citations
16.
Sidiqi, M Hasib, Mohammed A. Aljama, Dragan Jevremović, et al.. (2018). Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. Haematologica. 103(7). 1229–1234. 3 indexed citations
17.
Sidiqi, M Hasib, Mohammed A. Aljama, David S. Viswanatha, & David Dingli. (2018). T-cell large granular lymphocytic leukemia and plasma cell disorders. Haematologica. 104(3). e108–e110. 8 indexed citations
18.
Sidiqi, M Hasib, Mohammed A. Aljama, Dragan Jevremović, et al.. (2018). Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. Bone Marrow Transplantation. 54(3). 442–447. 5 indexed citations
19.
Aljama, Mohammed A., M Hasib Sidiqi, & David Dingli. (2018). Therapy for relapsed multiple myeloma. Panminerva Medica. 60(4). 174–184. 2 indexed citations
20.
Al‐Salem, Ahmed H., et al.. (2011). Strongyloides stercoralis hyperinfection in a post-renal transplant patient. Clinical and Experimental Gastroenterology. 4. 269–269. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nancy Bello Breakdown of academic impact, for papers by Sossana Delimpasi Breakdown of academic impact, for papers by Nobuya Hiraoka Breakdown of academic impact, for papers by Ami Patel Breakdown of academic impact, for papers by Anthony C Shelton Breakdown of academic impact, for papers by Shuichi Shirane Breakdown of academic impact, for papers by Robert Greiner Breakdown of academic impact, for papers by Luděk Pour Breakdown of academic impact, for papers by Zonghong Shao Breakdown of academic impact, for papers by Toshikazu Akioka
Rankless by CCL
2026